Braeburn Pharmaceuticals

OverviewSuggest Edit

Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals.

TypePrivate
Founded2012
HQPlymouth Meeting, PA, US
Websitebraeburnrx.com
Employee Ratings4.6

Latest Updates

Employees (est.) (May 2019)67(-4%)
Cybersecurity ratingBMore

Key People/Management at Braeburn Pharmaceuticals

Mike Derkacz

Mike Derkacz

President & CEO, Director
Louis Ricigliano

Louis Ricigliano

Chief Financial Officer
Paul Johnson

Paul Johnson

Chief Commercial Officer
Susan Franks

Susan Franks

SVP, Regulatory Affairs
Brian Hirsch

Brian Hirsch

General Counsel
Show more

Braeburn Pharmaceuticals Office Locations

Braeburn Pharmaceuticals has an office in Plymouth Meeting
Plymouth Meeting, PA, US (HQ)
450 Plymouth Rd #400
Show all (1)

Braeburn Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2012

Braeburn Pharmaceuticals total Funding

$110 m

Braeburn Pharmaceuticals latest funding size

$110 m

Time since last funding

4 years ago

Braeburn Pharmaceuticals investors

Braeburn Pharmaceuticals's latest funding round in January 2018 was reported to be $110 m. In total, Braeburn Pharmaceuticals has raised $110 m
Show all financial metrics

Braeburn Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Braeburn Pharmaceuticals Online and Social Media Presence

Embed Graph

Braeburn Pharmaceuticals Blogs

FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

  Prescription Drug User Fee Act (PDUFA) action date set for December 15, 2021. Plymouth Meeting, Pa. – June 26, … Read more... The post FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Di…

Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

  Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA) for BRIXADI … Read more... The post Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder appeared…

Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB

Plymouth Meeting, Pa. – December 10, 2020 – Braeburn announces that a tribunal appointed by the ICC International Court of … Read more... The post Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB appeared first on Braeburn.

Braeburn Receives Complete Response Letter for the NDA for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

  Plymouth Meeting, Pa. — December 2, 2020 — Braeburn announces that the U.S. Food and Drug Administration (FDA) issued … Read more... The post Braeburn Receives Complete Response Letter for the NDA for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid U…

Braeburn Appoints Brian Hirsch as General Counsel

Plymouth Meeting, Pa. —September 15, 2020—Braeburn announces that it has appointed Brian Hirsch as General Counsel and Corporate Secretary.… Read more... The post Braeburn Appoints Brian Hirsch as General Counsel appeared first on Braeburn.

Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

Plymouth Meeting, Pa. —June 1, 2020 — Braeburn announces that it has requested final approval from the U.S. Food and … Read more... The post Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder appeared first on …
Show more

Braeburn Pharmaceuticals Frequently Asked Questions

  • When was Braeburn Pharmaceuticals founded?

    Braeburn Pharmaceuticals was founded in 2012.

  • Who are Braeburn Pharmaceuticals key executives?

    Braeburn Pharmaceuticals's key executives are Mike Derkacz, Louis Ricigliano and Paul Johnson.

  • How many employees does Braeburn Pharmaceuticals have?

    Braeburn Pharmaceuticals has 67 employees.

  • Who are Braeburn Pharmaceuticals competitors?

    Competitors of Braeburn Pharmaceuticals include Kartos Therapeutics, Fysius Rugexperts and Polyplus-transfection.

  • Where is Braeburn Pharmaceuticals headquarters?

    Braeburn Pharmaceuticals headquarters is located at 450 Plymouth Rd #400, Plymouth Meeting.

  • Where are Braeburn Pharmaceuticals offices?

    Braeburn Pharmaceuticals has an office in Plymouth Meeting.

  • How many offices does Braeburn Pharmaceuticals have?

    Braeburn Pharmaceuticals has 1 office.